August 25, 2007
It’s no secret that researchers in both the commercial pharma and academic neuroscience communities are intent on designing new medicines to treat the growing populations of patients afflicted with central nervous system disorders such as Alzheimer’s disease, Parkinson’s disease, stroke, and brain tumors. And it’s also no secret that the biggest obstacle to the successful delivery of these specialized drug therapies is the blood brain barrier – a unique network of tightly packed endothelial cells that protects the brain from the many chemicals flowing within the blood.
What’s surprising, however, is that the blood brain barrier continues to be significantly disregarded as an essential area of focus within both Big Pharma and the academic neuroscience establishment. And the unfortunate byproduct of this neglect is a substantial over funding of neuroscience research projects that produce few commercially viable therapies that can effectively address the growing threat of many age-related neurological conditions.
In this program, we speak with Dr. William Pardridge, Professor of Medicine at the UCLA Brain Research Institute and founder of ArmaGen Technologies. Join us for an eye-opening discussion of the science and politics of blood brain barrier drug delivery, and learn more about some of the fascinating new areas of research and development in this critical, but very often overlooked, area of neuroscience.